# CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing

## Metadata
**Authors:** Danxin Wang, Wolfgang Sadee
**Journal:** Pharmacogenetics and genomics
**Date:** 2016 Jan
**DOI:** [10.1097/FPC.0000000000000183](https://doi.org/10.1097/FPC.0000000000000183)
**PMID:** 26488616
**PMCID:** PMC4674354
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674354/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC4674354/pdf/nihms726960.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC4674354/pdf/nihms726960.pdf)

## Abstract

Cytochrome P450 3A4 (CYP3A4) metabolizes 30–50% of clinically used drugs. Large interperson variability in CYP3A4 activity affects response to CYP3A4 substrate drugs. We had demonstrated that an intronic single nucleotide polymorphism (SNP) rs35599367 (CYP3A4*22, located in intron 6) reduces mRNA/protein expression; however, the underlying mechanism remained unknown. Here we show that CYP3A4*22 is associated with a twofold or greater increase in formation of a nonfunctional CYP3A4 alternative splice variant (aSV) with partial intron 6 retention in human liver (p=0.006), but not in small intestines. Consistent with this observation, in vitro transfection experiments with a CYP3A4 minigene (spanning from intron 5 to intron 7) demonstrated that plasmids carrying the rs35599367 minor T allele caused significantly greater intron 6 retention than the C allele in liver derived HepG2 cells, but not in intestine-derived LS-174T cells. These results indicate that tissue specific increased formation of nonfunctional aSV causes reduced CYP3A4 mRNA/protein expression in CYP3A4*22 carriers.

Keywords: CYP3A4, CYP3A4*22 allele, gene expression, polymorphism, alternative splicing

## Supplementary Material

## Acknowledgments

Source of funding: This work was supported by National Institute of Health (NIH) grants U01 GM 092655, and partially by grant from the National Center for Research Resources (UL 1RR025755). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources of the National Institute of Health.

## Footnotes

## Associated Data

*This section collects any data citations, data availability statements, or supplementary materials included in this article.*

### Supplementary Materials

### Supplementary Materials

## References

1. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141. doi: 10.1016/j.pharmthera.2012.12.007.  [DOI](https://doi.org/10.1016/j.pharmthera.2012.12.007) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23333322/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacol%20Ther&title=Cytochrome%20P450%20enzymes%20in%20drug%20metabolism:%20regulation%20of%20gene%20expression,%20enzyme%20activities,%20and%20impact%20of%20genetic%20variation&author=UM%20Zanger&author=M%20Schwab&volume=138&publication_year=2013&pages=103-141&pmid=23333322&doi=10.1016/j.pharmthera.2012.12.007&)

2. Werk AN, Lefeldt S, Bruckmueller H, Hemmrich-Stanisak G, Franke A, Roos M, Kuchle C, Steubl D, Schmaderer C, Brasen JH, et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther. 2014;95:416–422. doi: 10.1038/clpt.2013.210.  [DOI](https://doi.org/10.1038/clpt.2013.210) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24126681/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=Identification%20and%20characterization%20of%20a%20defective%20CYP3A4%20genotype%20in%20a%20kidney%20transplant%20patient%20with%20severely%20diminished%20tacrolimus%20clearance&author=AN%20Werk&author=S%20Lefeldt&author=H%20Bruckmueller&author=G%20Hemmrich-Stanisak&author=A%20Franke&volume=95&publication_year=2014&pages=416-422&pmid=24126681&doi=10.1038/clpt.2013.210&)

3. Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014;96:340–348. doi: 10.1038/clpt.2014.129.  [DOI](https://doi.org/10.1038/clpt.2014.129) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24926778/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=Functional%20gene%20variants%20of%20CYP3A4&author=AN%20Werk&author=I%20Cascorbi&volume=96&publication_year=2014&pages=340-348&pmid=24926778&doi=10.1038/clpt.2014.129&)

4. Wang D, Sadee W. The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy. J Pers Med. 2012;2:175–191. doi: 10.3390/jpm2040175.  [DOI](https://doi.org/10.3390/jpm2040175) | [PMC free article](/articles/PMC3901424/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24466438/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Pers%20Med&title=The%20Making%20of%20a%20CYP3A%20Biomarker%20Panel%20for%20Guiding%20Drug%20Therapy&author=D%20Wang&author=W%20Sadee&volume=2&publication_year=2012&pages=175-191&pmid=24466438&doi=10.3390/jpm2040175&)

5. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274–286. doi: 10.1038/tpj.2010.28.  [DOI](https://doi.org/10.1038/tpj.2010.28) | [PMC free article](/articles/PMC3248744/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20386561/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics%20J&title=Intronic%20polymorphism%20in%20CYP3A4%20affects%20hepatic%20expression%20and%20response%20to%20statin%20drugs&author=D%20Wang&author=Y%20Guo&author=SA%20Wrighton&author=GE%20Cooke&author=W%20Sadee&volume=11&publication_year=2011&pages=274-286&pmid=20386561&doi=10.1038/tpj.2010.28&)

6. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci. 2013;38:349–354. doi: 10.2131/jts.38.349.  [DOI](https://doi.org/10.2131/jts.38.349) | [PMC free article](/articles/PMC4018728/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23665933/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Toxicol%20Sci&title=CYP3A4%20intron%206%20C>T%20polymorphism%20(CYP3A4*22)%20is%20associated%20with%20reduced%20CYP3A4%20protein%20level%20and%20function%20in%20human%20liver%20microsomes&author=M%20Okubo&author=N%20Murayama&author=M%20Shimizu&author=T%20Shimada&author=FP%20Guengerich&volume=38&publication_year=2013&pages=349-354&pmid=23665933&doi=10.2131/jts.38.349&)

7. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, van Schaik RH. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics. 2013;14:137–149. doi: 10.2217/pgs.12.202.  [DOI](https://doi.org/10.2217/pgs.12.202) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23327575/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics&title=CYP3A4%20intron%206%20C>T%20SNP%20(CYP3A4*22)%20encodes%20lower%20CYP3A4%20activity%20in%20cancer%20patients,%20as%20measured%20with%20probes%20midazolam%20and%20erythromycin&author=L%20Elens&author=A%20Nieuweboer&author=SJ%20Clarke&author=KA%20Charles&author=AJ%20de%20Graan&volume=14&publication_year=2013&pages=137-149&pmid=23327575&doi=10.2217/pgs.12.202&)

8. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, Van Schaik RH, Kolovou G, Manolopoulos VG. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Drug Metabol Drug Interact. 2014 doi: 10.1515/dmdi-2014-0021.  [DOI](https://doi.org/10.1515/dmdi-2014-0021) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/25274942/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Metabol%20Drug%20Interact&title=No%20effect%20of%20CYP3A4%20intron%206%20C>T%20polymorphism%20(CYP3A4*22)%20on%20lipid-lowering%20response%20to%20statins%20in%20Greek%20patients%20with%20primary%20hypercholesterolemia&author=G%20Ragia&author=V%20Kolovou&author=A%20Tavridou&author=L%20Elens&author=AD%20Tselepis&publication_year=2014&pmid=25274942&doi=10.1515/dmdi-2014-0021&)

9. Li D, Gaedigk R, Hart SN, Leeder JS, Zhong XB. The role of CYP3A4 mRNA transcript with shortened 3′-untranslated region in hepatocyte differentiation, liver development, and response to drug induction. Mol Pharmacol. 2012;81:86–96. doi: 10.1124/mol.111.074393.  [DOI](https://doi.org/10.1124/mol.111.074393) | [PMC free article](/articles/PMC3250109/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21998292/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol%20Pharmacol&title=The%20role%20of%20CYP3A4%20mRNA%20transcript%20with%20shortened%203%E2%80%B2-untranslated%20region%20in%20hepatocyte%20differentiation,%20liver%20development,%20and%20response%20to%20drug%20induction&author=D%20Li&author=R%20Gaedigk&author=SN%20Hart&author=JS%20Leeder&author=XB%20Zhong&volume=81&publication_year=2012&pages=86-96&pmid=21998292&doi=10.1124/mol.111.074393&)

10. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet. 2014;23:268–278. doi: 10.1093/hmg/ddt417.  [DOI](https://doi.org/10.1093/hmg/ddt417) | [PMC free article](/articles/PMC3857955/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23985325/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hum%20Mol%20Genet&title=Common%20CYP2D6%20polymorphisms%20affecting%20alternative%20splicing%20and%20transcription:%20long-range%20haplotypes%20with%20two%20regulatory%20variants%20modulate%20CYP2D6%20activity&author=D%20Wang&author=MJ%20Poi&author=X%20Sun&author=A%20Gaedigk&author=JS%20Leeder&volume=23&publication_year=2014&pages=268-278&pmid=23985325&doi=10.1093/hmg/ddt417&)

11. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008;112:1013–1021. doi: 10.1182/blood-2008-03-144899.  [DOI](https://doi.org/10.1182/blood-2008-03-144899) | [PMC free article](/articles/PMC2515137/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18523153/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood&title=Regulatory%20polymorphism%20in%20vitamin%20K%20epoxide%20reductase%20complex%20subunit%201%20(VKORC1)%20affects%20gene%20expression%20and%20warfarin%20dose%20requirement&author=D%20Wang&author=H%20Chen&author=KM%20Momary&author=LH%20Cavallari&author=JA%20Johnson&volume=112&publication_year=2008&pages=1013-1021&pmid=18523153&doi=10.1182/blood-2008-03-144899&)

12. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, Lee ML, Xiao T, Papp A, Wang D, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A. 2007;104:20552–20557. doi: 10.1073/pnas.0707106104.  [DOI](https://doi.org/10.1073/pnas.0707106104) | [PMC free article](/articles/PMC2154469/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18077373/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&title=Polymorphisms%20in%20human%20dopamine%20D2%20receptor%20gene%20affect%20gene%20expression,%20splicing,%20and%20neuronal%20activity%20during%20working%20memory&author=Y%20Zhang&author=A%20Bertolino&author=L%20Fazio&author=G%20Blasi&author=A%20Rampino&volume=104&publication_year=2007&pages=20552-20557&pmid=18077373&doi=10.1073/pnas.0707106104&)

13. Papp AC, Pinsonneault JK, Wang D, Newman LC, Gong Y, Johnson JA, Pepine CJ, Kumari M, Hingorani AD, Talmud PJ, et al. Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One. 2012;7:e31930. doi: 10.1371/journal.pone.0031930.  [DOI](https://doi.org/10.1371/journal.pone.0031930) | [PMC free article](/articles/PMC3293889/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22403620/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20One&title=Cholesteryl%20Ester%20Transfer%20Protein%20(CETP)%20polymorphisms%20affect%20mRNA%20splicing,%20HDL%20levels,%20and%20sex-dependent%20cardiovascular%20risk&author=AC%20Papp&author=JK%20Pinsonneault&author=D%20Wang&author=LC%20Newman&author=Y%20Gong&volume=7&publication_year=2012&pages=e31930&pmid=22403620&doi=10.1371/journal.pone.0031930&)

14. Sadee W, Wang D, Papp AC, Pinsonneault JK, Smith RM, Moyer RA, Johnson AD. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther. 2011;89:355–365. doi: 10.1038/clpt.2010.314.  [DOI](https://doi.org/10.1038/clpt.2010.314) | [PMC free article](/articles/PMC3251919/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21289622/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=Pharmacogenomics%20of%20the%20RNA%20world:%20structural%20RNA%20polymorphisms%20in%20drug%20therapy&author=W%20Sadee&author=D%20Wang&author=AC%20Papp&author=JK%20Pinsonneault&author=RM%20Smith&volume=89&publication_year=2011&pages=355-365&pmid=21289622&doi=10.1038/clpt.2010.314&)
